Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor

Michael B. Dilling, Peter Dias, David N. Shapiro, Glen S. Germain, Randall K. Johnson, Peter J Houghton

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50% inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to >10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rhl, which was resistant to RAP in serum-containing medium (50% inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on completing with the cytosolic FK506-binding protein for activity.

Original languageEnglish (US)
Pages (from-to)903-907
Number of pages5
JournalCancer Research
Volume54
Issue number4
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

IGF Type 1 Receptor
Rhabdomyosarcoma
Sirolimus
Growth
Cell Line
Inhibitory Concentration 50
Alveolar Rhabdomyosarcoma
Paracrine Communication
Embryonal Rhabdomyosarcoma
Tacrolimus Binding Proteins
Somatomedin Receptors
Tacrolimus
Immunosuppressive Agents
Cell Proliferation
Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor. / Dilling, Michael B.; Dias, Peter; Shapiro, David N.; Germain, Glen S.; Johnson, Randall K.; Houghton, Peter J.

In: Cancer Research, Vol. 54, No. 4, 01.01.1994, p. 903-907.

Research output: Contribution to journalArticle

Dilling, Michael B. ; Dias, Peter ; Shapiro, David N. ; Germain, Glen S. ; Johnson, Randall K. ; Houghton, Peter J. / Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor. In: Cancer Research. 1994 ; Vol. 54, No. 4. pp. 903-907.
@article{9ab79ec851c3478cad2fe92aba1046f8,
title = "Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor",
abstract = "We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50{\%} inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to >10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rhl, which was resistant to RAP in serum-containing medium (50{\%} inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on completing with the cytosolic FK506-binding protein for activity.",
author = "Dilling, {Michael B.} and Peter Dias and Shapiro, {David N.} and Germain, {Glen S.} and Johnson, {Randall K.} and Houghton, {Peter J}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
pages = "903--907",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor

AU - Dilling, Michael B.

AU - Dias, Peter

AU - Shapiro, David N.

AU - Germain, Glen S.

AU - Johnson, Randall K.

AU - Houghton, Peter J

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50% inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to >10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rhl, which was resistant to RAP in serum-containing medium (50% inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on completing with the cytosolic FK506-binding protein for activity.

AB - We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50% inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to >10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rhl, which was resistant to RAP in serum-containing medium (50% inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on completing with the cytosolic FK506-binding protein for activity.

UR - http://www.scopus.com/inward/record.url?scp=0028328655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028328655&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 903

EP - 907

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -